The role of hepatitis C virus (HCV) infection in fulminant hepatic failure is controversial. The frequency of serum HCV RNA positivity in previously reported patients with fulminant hepatic failure (FHF) of indeterminate cause ranged from 0 to 12% in the United States and Europe and from 43% to 59%
Hepatitis C virus RNA in blood donor sera detected by the polymerase chain reaction: Comparison with supplementary hepatitis C antibody assays
✍ Scribed by Dr. Anders Widell; Ann-Sofie Månsson; Gunnar Sundstrom; Bengt Göran Hansson; Erik Nordenfelt
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 644 KB
- Volume
- 35
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The low specificity of screening ELISAs for antibodies to hepatitis C virus in blood donors has called for confirmatory tests. Two types of supplementary antibody assays are available, recombinant immunoblot assays (RIBA‐1 and RIBA‐2) and an antibody consumption test referred to as a neutralization assay. Amplification of viral nucleic acid by the polymerase chain reaction (PCR) provides an antibody independent mode of detecting viral infection. We applied reverse transcription‐double PCR to detect an HCV 5'‐noncoding viral RNA sequence in serum specimens and compared PCR findings with confirmatory antibody tests. This study includes sera from 37 blood donors found positive by the Ortho anti‐HCV (C100‐3) ELISA out of 14,591 donations. Of the 37 positive sera, 8 were positive by RIBA‐1 and 1 further by RIBA‐2. Seven of the RIBA positive sera contained HCV RNA by PCR. Among the 8 indeterminate and the 21 negative donor sera by RIBA‐I, no PCR positive serum was found. The 37 anti‐HCV positive donor sera identified by Ortho ELISA were also tested by Abbott anti‐HCV (C100‐3) ELISA whereby 22 were positive. Of these 22 sera plus 1 further with ELISA OD just below cutoff, 8 were positive by the “neutralization assay,” (Abbott Laboratories, North Chicago, IL, USA) and 6 of these, including the borderline serum, were PCR positive. One of the two neutralizable but PCR negative sera was RIBA positive and the other was indeterminate. However, one ELIS. A (Abbott Laboratories) positive (OD 1.99) serum was not neutralizable but nevertheless contained HCV RNA by PCR. Thus in blood donor sera, anti‐HCV (C100‐3) reactivity confirmed by RIBA or “neutralization” correlated well with the presence of HCV RNA.
📜 SIMILAR VOLUMES
## Abstract The mean prevalence of anti‐hepatitis C virus (HCV) in Italy is 0.87%. It reaches 2% in Campania, Southern Italy. Approximately 50% of community acquired non‐A, non‐B (NANB) hepatitis cannot be associated with known parenteral exposure. A recent Italian study has shown that the only dem
Three PCR methods based on the GB virus-C/ hepatitis G virus (GBV-C/HGV) 5ЈUTR and NS3 genomic region were used for the detection of GBV-C/HGV RNA in serum of 62 patients with chronic hepatitis C virus (HCV) infection. Ten of 62 (16%) patients were found to have GBV-C/ HGV RNA, which was confirmed b
Three oligonucleotide primer combinations selected from the 5' noncoding, the nucleocapsid and the putative nonstructural regions of the hepatitis C virus genome were compared in a nested polymerase chain reaction assay with respect to sensitivity and specificity for the detection of viral RNA in ch
## Abstract A rapid and simple RNA‐capture polymerase chain reaction assay (RCPA) for detection of hepatitis C virus (HCV) is described. The assay detects specifically the presence of (near) full length genomic RNA of HCV by capturing HCV‐RNA at the 3′ terminal end on magnetic beads, followed by cD
The combination of reverse transcription and polymerase chain reaction is a very powerful tool for the detection of hepatitis C virus RNA in sera of patients with hepatitis C virus infection. However, when studying the presence of this virus in tissue using polymerase chain reaction, it may be diffi